EQS-Adhoc: M1 Kliniken AG: M1 Kliniken AG: HAEMATO AG sells its 100% subsidiary HAEMATO Pharm GmbH to PHOENIX group
|
EQS-Ad-hoc: M1 Kliniken AG / Key word(s): Disposal/Investment Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
M1 Kliniken AG announces that its 85% subsidiary, HAEMATO AG, today signed an agreement for the sale of its wholly owned subsidiary HAEMATO Pharm GmbH to the PHOENIX group, one of Europe’s leading healthcare providers headquartered in Mannheim. The completion of the transaction remains subject to the customary antitrust approvals. The parties have agreed not to disclose the financial details of the transaction. With this transaction, M1 Kliniken AG is consistently pursuing its strategic course to position itself as a globally leading, vertically integrated pure-play provider in the field of medical aesthetics. Contact: Attila Strauss, Management Board Corporate Communications E-Mail: ir@m1-kliniken.de End of Inside Information
16-Oct-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | M1 Kliniken AG |
| Grünauer Straße 5 | |
| 12557 Berlin | |
| Germany | |
| Phone: | +49 (0)30 347 47 44 14 |
| Fax: | +49 (0)30 347 47 44 17 |
| E-mail: | ir@m1-kliniken.de |
| Internet: | https://www.m1-kliniken.de |
| ISIN: | DE000A0STSQ8 |
| WKN: | A0STSQ |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2214474 |
| End of Announcement | EQS News Service |
|
|
2214474 16-Oct-2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 77,27 | 159,59 | 314,61 | 285,29 | 316,32 | 339,18 | 349,00 | |
| EBITDA1,2 | 11,33 | 8,89 | 17,82 | 15,41 | 21,01 | 31,96 | 33,70 | |
| EBITDA-Margin3 | 14,66 | 5,57 | 5,66 | 5,40 | 6,64 | 9,42 | 9,66 | |
| EBIT1,4 | 7,93 | 4,41 | 12,13 | 9,35 | 15,70 | 26,75 | 28,20 | |
| EBIT-Margin5 | 10,26 | 2,76 | 3,86 | 3,28 | 4,96 | 7,89 | 8,08 | |
| Net Profit (Loss)1 | 9,73 | 7,43 | 10,88 | 7,07 | 11,67 | 17,79 | 18,80 | |
| Net-Margin6 | 12,59 | 4,66 | 3,46 | 2,48 | 3,69 | 5,25 | 5,39 | |
| Cashflow1,7 | -5,37 | 9,54 | 15,68 | 20,77 | 7,81 | 30,55 | 24,50 | |
| Earnings per share8 | 0,56 | 0,37 | 0,45 | 0,22 | 0,54 | 0,85 | 0,93 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,50 | 0,50 | 0,50 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: wetreu NTRG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| M1 Kliniken | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A0STSQ | DE000A0STSQ8 | AG | 379,51 Mio € | 14.09.2015 | Kaufen | 9F4MCHV9+6R |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 15,58 | 27,45 | 0,57 | 44,93 | 3,94 | 12,42 | 1,12 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,50 | 0,50 | 0,50 | 2,59% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 16.07.2025 | 05.06.2025 | 09.09.2025 | 18.11.2025 | 21.05.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +28,84% | +31,86% | +16,39% | +20,37% | +311,06% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
